Trial Information

Summary: Phase II Trial Utilizing Idarubicin in Combination with High-Dose Ara-C for Induction Therapy for Adult Acute Myelogenous Leukemia

The purpose of this research study is to 1) determine the complete remission rate, 2) to determine the number of courses of treatment required to enter remission, 3) to determine the side effects of the regimen, and 4) to determine the ability of patients with AML treated with this regimen to receive further post remission chemotherapy (consolidation chemotherapy).

Patient Inclusion/Exclusion Criteria:

- Age 16 to 60 years - Diagnosed with acute myelogenous leukemia (AML) - No previous chemotherapy or radiation therapy treatment for AML except Hydroxyurea - Patients will prior myelodysplasia and secondary AML are eligible - Patient must be in otherwise generally good health
- See http://clinicaltrials.coh.org for additional information.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 2, 2008 at 2:50:43 PM